Contraline is a biotech company focused on developing male contraceptive solutions, including their flagship product ADAM, a non-surgical, reversible male contraceptive. The company's approach involves developing minimally invasive procedures and devices that provide long-term contraceptive options for men. Contraline aims to expand contraceptive choices and shared responsibility in family planning by providing safe, effective, and reversible male birth control alternatives. Their technology represents a significant advancement in male reproductive health options.
ContralinePioneering male birth control has received investment from 1 venture capital firm.
Biotechnology company developing innovative male contraceptive solutions including non-hormonal birth control methods.
ContralinePioneering male birth control has received investment from Amboy Street Ventures. These venture capital firms and investors provide both capital and strategic support.
ContralinePioneering male birth control has raised $23M in total funding, with their most recent round being a Series A. The company operates in the Biotech sector.
ContralinePioneering male birth control was founded in 2015 and is headquartered in Charlottesville, VA.
ContralinePioneering male birth control operates in the Biotech sector. Biotechnology company developing innovative male contraceptive solutions including non-hormonal birth control methods.
